Envestnet Asset Management Inc. Lowers Holdings in Cencora, Inc. $COR

Envestnet Asset Management Inc. reduced its stake in shares of Cencora, Inc. (NYSE:COR) by 3.5% during the 3rd quarter, HoldingsChannel reports. The fund owned 525,162 shares of the company’s stock after selling 18,941 shares during the period. Envestnet Asset Management Inc.’s holdings in Cencora were worth $164,129,000 at the end of the most recent quarter.

Several other hedge funds have also modified their holdings of the stock. Vanguard Group Inc. raised its stake in Cencora by 5.3% during the second quarter. Vanguard Group Inc. now owns 22,479,041 shares of the company’s stock worth $6,740,340,000 after purchasing an additional 1,125,661 shares during the period. Geode Capital Management LLC raised its position in shares of Cencora by 6.3% in the 2nd quarter. Geode Capital Management LLC now owns 4,787,609 shares of the company’s stock worth $1,429,772,000 after buying an additional 284,229 shares during the period. Norges Bank acquired a new position in Cencora in the second quarter valued at $695,215,000. Viking Global Investors LP grew its position in Cencora by 95.0% during the second quarter. Viking Global Investors LP now owns 2,081,732 shares of the company’s stock valued at $624,207,000 after acquiring an additional 1,013,913 shares during the period. Finally, Amundi grew its position in Cencora by 17.0% during the second quarter. Amundi now owns 1,720,278 shares of the company’s stock valued at $500,893,000 after acquiring an additional 249,742 shares during the period. 97.52% of the stock is owned by institutional investors and hedge funds.

Cencora Price Performance

Shares of COR stock opened at $359.15 on Friday. The firm has a fifty day simple moving average of $345.91 and a 200-day simple moving average of $325.92. The company has a market capitalization of $69.67 billion, a PE ratio of 43.17, a price-to-earnings-growth ratio of 1.63 and a beta of 0.68. Cencora, Inc. has a twelve month low of $237.71 and a twelve month high of $377.54. The company has a current ratio of 0.92, a quick ratio of 0.55 and a debt-to-equity ratio of 3.62.

Cencora (NYSE:COR) last issued its quarterly earnings data on Wednesday, February 4th. The company reported $4.08 EPS for the quarter, topping analysts’ consensus estimates of $4.04 by $0.04. The firm had revenue of $85.93 billion for the quarter, compared to analyst estimates of $86.12 billion. Cencora had a net margin of 0.50% and a return on equity of 176.54%. The firm’s revenue was up 5.5% compared to the same quarter last year. During the same quarter in the previous year, the business posted $3.73 EPS. Equities research analysts anticipate that Cencora, Inc. will post 15.37 earnings per share for the current fiscal year.

Cencora Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, March 2nd. Shareholders of record on Friday, February 13th will be paid a dividend of $0.60 per share. This represents a $2.40 dividend on an annualized basis and a yield of 0.7%. The ex-dividend date is Friday, February 13th. Cencora’s dividend payout ratio (DPR) is 30.19%.

Insiders Place Their Bets

In other Cencora news, EVP Elizabeth S. Campbell sold 3,351 shares of Cencora stock in a transaction that occurred on Friday, December 19th. The stock was sold at an average price of $342.10, for a total transaction of $1,146,377.10. Following the sale, the executive vice president directly owned 23,891 shares in the company, valued at $8,173,111.10. The trade was a 12.30% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Robert P. Mauch sold 5,096 shares of the stock in a transaction that occurred on Tuesday, January 20th. The shares were sold at an average price of $354.73, for a total value of $1,807,704.08. Following the transaction, the chief executive officer owned 66,726 shares of the company’s stock, valued at approximately $23,669,713.98. This trade represents a 7.10% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 20,316 shares of company stock worth $7,151,265 in the last three months. 0.38% of the stock is owned by insiders.

Trending Headlines about Cencora

Here are the key news stories impacting Cencora this week:

• Positive Sentiment: Q1 2026 earnings call highlighted strong U.S. growth that offset international headwinds; management commentary helped support the upbeat tone after results. Cencora Inc (COR) Q1 2026 Earnings Call Highlights
• Positive Sentiment: Cencora closed its deal with OneOncology; coverage of the terms characterizes the agreement as reflecting trust between parties, which supports the company’s oncology services strategy and potential revenue synergies. As Cencora Closes With OneOncology
• Neutral Sentiment: Evercore ISI set a new $420 price target (down from $440) but kept an “outperform” rating — the target implies meaningful upside from current levels despite the trim. Cencora Given New $420.00 Price Target at Evercore ISI
• Neutral Sentiment: Market write-ups and stock-flow coverage are highlighting the mix of EPS beats and revenue dynamics as reasons for the intraday move, keeping attention on upcoming guidance and international performance. Cencora stock trades up, here is why
• Negative Sentiment: Cencora missed Q4 CY2025 revenue estimates, which tempers enthusiasm from the EPS beat and raises questions about near-term revenue momentum. Cencora misses Q4 revenue estimates
• Negative Sentiment: Recent intraday coverage noted the stock underperformed peers on Wednesday, suggesting investors are watching competitive execution and margin trends across the sector. Cencora underperforms competitors

Analysts Set New Price Targets

Several research firms have recently weighed in on COR. Jefferies Financial Group raised Cencora from an “underperform” rating to a “buy” rating in a research note on Thursday, January 22nd. TD Cowen lifted their price target on shares of Cencora from $350.00 to $400.00 and gave the company a “buy” rating in a research report on Monday, November 10th. Wall Street Zen lowered shares of Cencora from a “buy” rating to a “hold” rating in a research report on Friday, November 28th. Mizuho raised their target price on shares of Cencora from $340.00 to $380.00 and gave the company an “outperform” rating in a research note on Thursday, November 6th. Finally, Evercore decreased their price target on shares of Cencora from $440.00 to $420.00 and set an “outperform” rating for the company in a research report on Thursday. One research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $394.75.

About Cencora

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.